Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells.
Purity:
>99%, Endotoxin < 1 EU/µg
* VAT and and shipping costs not included. Errors and price changes excepted
